Endurant Capital Management LP Grows Holdings in Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Endurant Capital Management LP Grows Holdings in Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Endurant Capital Management LP increased its holdings in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 43,250 shares of the company's stock after buying an additional 453 shares during the period. Endurant Capital Management LP owned about 0.07% of Global Blood Therapeutics worth $1,498,000 at the end of the most recent quarter.
Endurant Capital Management LP在最近向美國證券交易委員會提交的13F文件中顯示，該公司在第一季度將其持有的全球血液療法公司（納斯達克股票代碼：GBT — 獲取評級）的股票增加了1.1％。該公司在此期間又購買了453股股票後，擁有該公司43,250股股票。截至最近一個季度末，Endurant Capital Management LP擁有全球血液療法約0.07％的股份，價值149.8萬美元。
Several other large investors have also recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. increased its stake in Global Blood Therapeutics by 31.8% during the 4th quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company's stock worth $55,000 after buying an additional 450 shares during the period. New York State Common Retirement Fund increased its stake in Global Blood Therapeutics by 1.1% during the 1st quarter. New York State Common Retirement Fund now owns 43,552 shares of the company's stock worth $1,509,000 after buying an additional 482 shares during the period. Arizona State Retirement System increased its stake in Global Blood Therapeutics by 3.7% during the 1st quarter. Arizona State Retirement System now owns 15,678 shares of the company's stock worth $543,000 after buying an additional 560 shares during the period. Lazard Asset Management LLC increased its stake in Global Blood Therapeutics by 31.4% during the 4th quarter. Lazard Asset Management LLC now owns 2,579 shares of the company's stock worth $75,000 after buying an additional 617 shares during the period. Finally, Nisa Investment Advisors LLC increased its position in shares of Global Blood Therapeutics by 75.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after purchasing an additional 650 shares during the last quarter.
其他幾位大型投資者最近也增加了或減少了在該業務中的股份。Advisor Group Holdings Inc.在第四季度將其在全球血液療法的股份增加了31.8％。Advisor Group Holdings Inc.在此期間又購買了450股股票後，現在擁有該公司1,865股股票，價值55,000美元。紐約州共同退休基金在第一季度將其在全球血液療法的股份增加了1.1％。紐約州共同退休基金在此期間又購買了482股股票後，現在擁有該公司43,552股股票，價值1,509,000美元。亞利桑那州退休系統在第一季度將其在全球血液療法的股份增加了3.7％。亞利桑那州退休系統在此期間又購買了560股股票後，現在擁有該公司15,678股股票，價值54.3萬美元。拉扎德資產管理有限責任公司在第四季度將其在全球血液療法的股份增加了31.4％。拉扎德資產管理有限責任公司在此期間又購買了617股股票後，現在擁有該公司2579股股票，價值7.5萬美元。最後，Nisa Investment Advisors LLC在第一季度將其在Global Blood Therapeutics的股票持倉增加了75.6％。Nisa Investment Advisors LLC在上個季度又購買了650股股票後，現在擁有該公司1,510股股票，價值52,000美元。
Global Blood Therapeutics Stock Up 0.2 %
全球血液療法股票上漲0.2％
Shares of NASDAQ:GBT opened at $67.87 on Tuesday. The stock has a market cap of $4.58 billion, a P/E ratio of -13.55 and a beta of 0.46. The firm has a fifty day moving average price of $52.27 and a 200 day moving average price of $37.71. The company has a debt-to-equity ratio of 4.92, a current ratio of 6.88 and a quick ratio of 6.17. Global Blood Therapeutics, Inc. has a 1-year low of $21.65 and a 1-year high of $73.02.
納斯達克股票代碼：GBT週二開盤價爲67.87美元。該股的市值爲45.8億美元，市盈率爲-13.55，貝塔值爲0.46。該公司的五十天移動平均價格爲52.27美元，200天移動平均價格爲37.71美元。該公司的負債權益比率爲4.92，流動比率爲6.88，速動比率爲6.17。Global Blood Therapeutics, Inc.的1年低點爲21.65美元，1年高點爲73.02美元。
Analyst Upgrades and Downgrades
分析師升級和降級
A number of equities research analysts have commented on GBT shares. Oppenheimer downgraded shares of Global Blood Therapeutics to a "market perform" rating in a research report on Monday, August 15th. Cowen downgraded shares of Global Blood Therapeutics to a "market perform" rating and increased their price objective for the company from $67.00 to $68.50 in a research report on Tuesday, August 9th. JPMorgan Chase & Co. dropped their price objective on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 28th. Guggenheim increased their price objective on shares of Global Blood Therapeutics to $72.00 in a research report on Monday, August 15th. Finally, Wells Fargo & Company downgraded shares of Global Blood Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price objective for the company from $66.00 to $68.50 in a research report on Tuesday, August 9th. Twelve investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Global Blood Therapeutics currently has a consensus rating of "Hold" and an average target price of $65.50.
許多股票研究分析師對GBT股票發表了評論。奧本海默在8月15日星期一的一份研究報告中將環球血療法的股票評級下調至 “市場表現”。考恩在8月9日星期二的一份研究報告中將Global Blood Therapeutics的股票評級下調至 “市場表現”，並將該公司的目標股價從67.00美元上調至68.50美元。摩根大通在6月28日星期二的一份研究報告中將Global Blood Therapeutics股票的目標股價從39.00美元下調至36.00美元，並對該股設定了 “中性” 評級。古根海姆在8月15日星期一的一份研究報告中將Global Blood Therapeutics股票的目標股價提高至72.00美元。最後，富國銀行在8月9日星期二的一份研究報告中將Global Blood Therapeutics的股票評級從 “增持” 下調至 “同等權重”，並將該公司的目標股價從66.00美元上調至68.50美元。十二位投資分析師對該股進行了持倉評級，五位投資分析師對該公司進行了買入評級。根據MarketBeat.com的數據，Global Blood Therapeutics目前的共識評級爲 “持有”，平均目標價爲65.50美元。
Insider Transactions at Global Blood Therapeutics
環球血液療法的內幕交易
In other news, insider Nazila Habibizad sold 4,678 shares of the firm's stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $67.19, for a total value of $314,314.82. Following the completion of the sale, the insider now owns 8,918 shares in the company, valued at approximately $599,200.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Philip A. Pizzo sold 1,260 shares of the firm's stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $27.25, for a total value of $34,335.00. Following the completion of the sale, the director now owns 9,112 shares in the company, valued at approximately $248,302. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Nazila Habibizad sold 4,678 shares of the stock in a transaction dated Thursday, August 18th. The shares were sold at an average price of $67.19, for a total transaction of $314,314.82. Following the completion of the transaction, the insider now owns 8,918 shares of the company's stock, valued at approximately $599,200.42. The disclosure for this sale can be found here. Company insiders own 4.90% of the company's stock.
在其他新聞方面，內部人士納齊拉·哈比比扎德在8月18日星期四的一筆交易中出售了該公司4,678股股票。這些股票的平均售價爲67.19美元，總價值爲314,314.82美元。出售完成後，知情人現在擁有該公司的8,918股股份，價值約599,200.42美元。該交易已在向美國證券交易委員會提交的一份文件中披露，可通過此超鏈接訪問該文件。在其他新聞方面，董事菲利普·皮佐在6月21日星期二的一筆交易中出售了該公司1,260股股票。這些股票的平均售價爲27.25美元，總價值爲34,335.00美元。出售完成後，該董事現在擁有該公司的9,112股股份，價值約248,302美元。該交易已在向美國證券交易委員會提交的一份文件中披露，可通過此超鏈接訪問該文件。此外，內部人士納齊拉·哈比比扎德在8月18日星期四的一筆交易中出售了4,678股股票。這些股票的平均售價爲67.19美元，總交易額爲314,314.82美元。交易完成後，知情人現在擁有該公司8,918股股票，價值約599,200.42美元。此次出售的披露可以在這裏找到。公司內部人士擁有公司4.90％的股份。
About Global Blood Therapeutics
關於全球血液療法
(Get Rating)
（獲取評級）
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics, Inc是一家生物製藥公司，致力於爲服務不足的鐮狀細胞病（SCD）患者社區發現、開發和提供治療方法。該公司提供Oxbryta片劑，這是一種口服，每天一次的SCD療法。它還評估了針對青少年和兒科SCD患者的II期臨床試驗中單劑量和多劑量的Oxbryta的安全性和藥代動力學。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- 免費獲取 StockNews.com 關於全球血液療法（GBT）的研究報告
- 這些股息成就者值得在你的投資組合中佔有一席之地嗎？
- Darden 餐廳走低路對抗通貨膨脹
- 爲什麼這三隻股票9月開盤火熱
- 通貨膨脹沒有區別，但其影響確實如此
- 3只評級下調的必備股票
Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics, Inc. (NASDAQ:GBT – Get Rating).
想看看還有哪些對沖基金持有GBT嗎？訪問HoldingSchannel.com，獲取全球血液療法公司（納斯達克股票代碼：GBT — 獲取評級）的最新13F申報和內幕交易。
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收全球血液療法日報的新聞和評級-在下方輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收全球血液療法及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。